Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2002 1
2004 1
2005 1
2006 4
2007 3
2008 3
2009 1
2010 2
2011 3
2012 3
2013 7
2014 4
2015 6
2016 4
2017 2
2018 4
2019 2
2020 3
2021 3
2022 2
2023 4
2024 1

Text availability

Article attribute

Article type

Publication date

Search Results

54 results

Results by year

Filters applied: . Clear all
Page 1
Tumor Microenvironment Landscape of NSCLC Reveals Resistance Mechanisms for Programmed Death-Ligand 1 Blockade After Chemoradiotherapy: A Multicenter Prospective Biomarker Study (WJOG11518L:SUBMARINE).
Haratani K, Nakamura A, Mamesaya N, Mitsuoka S, Yoneshima Y, Saito R, Tanizaki J, Fujisaka Y, Hata A, Tsuruno K, Sakamoto T, Teraoka S, Oki M, Watanabe H, Sato Y, Nakano Y, Otani T, Sakai K, Tomida S, Chiba Y, Ito A, Nishio K, Yamamoto N, Nakagawa K, Hayashi H. Haratani K, et al. Among authors: fujisaka y. J Thorac Oncol. 2023 Oct;18(10):1334-1350. doi: 10.1016/j.jtho.2023.06.012. Epub 2023 Jun 25. J Thorac Oncol. 2023. PMID: 37364849
Overall survival analysis of patients enrolled in a randomized phase III trial comparing gefitinib and erlotinib for previously treated advanced lung adenocarcinoma (WJOG5108LFS).
Katakami N, Yokoyama T, Morita S, Okamoto T, Urata Y, Hattori Y, Iwamoto Y, Sato Y, Ikeda N, Takahashi T, Daga H, Oguri T, Fujisaka Y, Nishino K, Sugawara S, Kozuki T, Oki M, Yamamoto N, Nakagawa K. Katakami N, et al. Among authors: fujisaka y. Int J Clin Oncol. 2023 Jan;28(1):79-88. doi: 10.1007/s10147-022-02266-x. Epub 2022 Nov 21. Int J Clin Oncol. 2023. PMID: 36414827 Clinical Trial.
Comparison Between Second- and Third-generation Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors as First-line Treatment in Patients With Non-small-cell Lung Cancer: A Retrospective Analysis.
Mitsuya S, Tsuruoka K, Kanaoka K, Funamoto T, Tsuji H, Matsunaga N, Nakamura T, Tamura Y, Imanishi M, Ikeda S, Fujisaka Y, Goto I, Imagawa A. Mitsuya S, et al. Among authors: fujisaka y. Anticancer Res. 2021 Oct;41(10):5137-5145. doi: 10.21873/anticanres.15331. Anticancer Res. 2021. PMID: 34593465
54 results